119830-47-6

Basic information

• Product Name: 2-Pyridinecarboxylicacid,5-amino-,ethylester(9CI)
• Synonyms: 2-Pyridinecarboxylicacid,5-amino-,ethylester(9CI);2-Pyridinecarboxylic acid, 5-aMino-, ethyl ester;Ethyl 5-aminopicolinate;5-amino-2-pyridinecarboxylic acid ethyl ester;5-Aminopyridine-2-carboxylic acid ethyl ester
• CAS NO: 119830-47-6
• Molecular Formula: C₈H₁₀N₂O₂
• Molecular Weight: 166.18
• Product Categories: GLYCINESCAFFOLD
• Mol File: 119830-47-6.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 340.789 °C at 760 mmHg
• Flash Point: 159.904 °C
• Appearance: /
• Density: 1.193 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.559
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2-Pyridinecarboxylicacid,5-amino-,ethylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxylicacid,5-amino-,ethylester(9CI)(119830-47-6)
• EPA Substance Registry System: 2-Pyridinecarboxylicacid,5-amino-,ethylester(9CI)(119830-47-6)

Safety Data

• Hazardous Substances Data: 119830-47-6(Hazardous Substances Data)

Usage

General Description

2-Pyridinecarboxylic acid, 5-amino-, ethyl ester (9CI) is a chemical compound with the molecular formula C8H10N2O2. It is commonly known as ethyl nicotinate and is used in the pharmaceutical industry as a vasodilator to improve blood circulation. It is also used as a flavoring agent in the food industry. Ethyl nicotinate is classified as an ester, and its chemical structure contains a pyridine ring with a carboxylic acid group and an amino group, as well as an ethyl ester functional group. It is a colorless to pale yellow liquid with a slight odor and is soluble in alcohol and ether. However, it is only sparingly soluble in water. Ethyl nicotinate is considered to be a relatively safe compound, but it can cause skin and eye irritation upon direct contact.

InChI:InChI=1/C8H10N2O2/c1-2-12-8(11)7-4-3-6(9)5-10-7/h3-5H,2,9H2,1H3

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 617-35-6 2-oxo-propionic acid ethyl ester 
• 30563-98-5 ethyl 5-nitropyridine-2-carboxylate 
• 21203-68-9 2-methyl-5-nitropyridine 
• 4548-45-2 2-chloro-5-nitropyridine 
• 30651-24-2 5-nitropicolinic acid 
• 24242-20-4 5-amino-pyridine-2-carboxylic acid 
• 64-17-5 ethanol 
• 1201916-73-5 C₁₈H₂₆N₂O₆ 
• 128072-93-5 ethyl 5-chloropyridine-2-carboxylate 
• 55338-73-3 5-amino-2-cyanopyridine 
• 13534-97-9 6-bromopyridine-3-amine 
• 1201916-72-4 2-bromo-5-(bis-Boc)aminopyridine 

Downstream Products

• 90866-96-9 ethyl N-ethyl-5-(p-toluenesulfonamido)pipecolate 
• 90866-95-8 ethyl 5-(N-acetyl-p-toluenesulfonamido)picolinate 
• 873651-92-4 (5-aminopyridin-2-yl)methanol 
• 1621060-24-9 5-(2-(4-fluorophenoxy)-4-(perfluoroethyl)benzamido)picolinic acid 
• 1621060-23-8 5-(2-(4-fluoro-2-methoxyphenoxy)-4-(perfluoroethyl)benzamido)picolinic acid 
• 1203486-73-0 tert-butyl 6-(morpholinomethyl)pyridin-3-ylcarbamate 
• 323578-38-7 tert-butyl N-[6-(hydroxymethyl)pyridin-3-yl]carbamate 
• 1078129-19-7 ethyl 5-(tert-butoxycarbonylamino)picolinate 
• 90866-93-6 ethyl 5-(p-toluenesulfonamido)picolinate 

Relevant articles and documents

Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents

The optimization of a new class of small molecule PCSK9 mRNA translation inhibitors is described. The potency, physicochemical properties, and off-target pharmacology associated with the hit compound (1) were improved by changes to two regions of the molecule. The last step in the synthesis of the congested amide center was enabled by three different routes. Subtle structural changes yielded significant changes in pharmacology and off-target margins. These efforts led to the identification of 7l and 7n with overall profiles suitable for in vivo evaluation. In a 14-day toxicology study, 7l demonstrated an improved safety profile vs lead 7f. We hypothesize that the improved safety profile is related to diminished binding of 7l to nontranslating ribosomes and an apparent improvement in transcript selectivity due to the lower strength of 7l stalling of off-target proteins.

JAK1 SELECTIVE KINASE INHIBITOR

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as JAK kinase inhibitors. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), and methods of using such compounds or compositions to treat respiratory conditions (e.g., asthma or COPD).

CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS

Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.